Physiopathology of myelodysplastic syndromes;Physiopathologie des syndromes myélodysplasiques

Pathologie Biologie

Volumn 50, Issue 4, 2002, Pages 261-267

  Claessens, Y E ^a   Fontenay Roupie, M ^a  

^a Hôpital Cochin ^*  (France)

Author keywords

Apoptosis; Erythropoiesis; Myelodysplastic syndromes

Indexed keywords

CD33 ANTIGEN; CD34 ANTIGEN; FAS ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; CONFERENCE PAPER; CYTOKINE PRODUCTION; ERYTHROID PRECURSOR CELL; GENE MUTATION; HEMATOPOIESIS; HUMAN; MYELODYSPLASTIC SYNDROME; ONCOGENE RAS; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; STROMA CELL;

EID: 0036268064     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0369-8114(02)00298-5     Document Type: Conference Paper

References (50)

1. Les syndrômes mydédysplasiques sont-ils des affections néoplasiques?
2. Impaired response of myelodysplastic marrow progenitors to stimulation with recombinant haematopoietic growth factors
3. Proliferation and differentiation of myelodysplatic CD34+ cells: Phenotypic subpopulations of marrow CD34+ cells
4. Role of cytokines in leukemic growth of myelodysplastic CD34+ cells
5. Response of myelodysplastic syndrome marrow progenitor cells to stimulation with cytokine combinations in a stroma-free long-term culture system
6. CD34+/CD36- cells from myelodysplasia patients have a limited capacity to proliferate but can differentiate in response to EPO and MGF stimulation
7. Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: Evidence for involvement at the hematopoietic stem cell level
8. In vitro studies of erythropoietin-dependent regulation of erythropoiesis in myelodysplastic syndromes
9. Erythropoiesis in myelodysplastic syndrome: Expression of receptors for erythropoietin and kit ligand
10. Analysis of the erythropoietin receptor gene in patients with myeloproliferative and myelodysplastic syndromes
11. Erythropoietin-induced activation of STAT5 is impaired in the myelodysplastic syndrome
12. Kit ligand improves in vitro erythropoiesis in myelodysplastic syndrome
13. Stem cell factor improvement of proliferation and maintenance of hemopoietic progenitors in myelodysplastic syndromes
14. The molecular mechanism of erythropoietin action
15. Jak2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin
16. IL-3-dependent regulation of Bcl-XL gene expression by STAT5 in a bone marrow derived cell line
17. Erythropoietin induces the tyrosine phosphorylation of GABI and its association with Shc, SHP2, SHIP and PI 3-K
18. Interleukin-3 induces phosphorylation of BAD through the protein kinase Akt
19. Signal transduction pathway by erythropoietin involves three forms of MAP kinase in UT-7 erythroleukemia cells
20. Increased Fas/CD95 expression and functional erythropoietin receptor transduction pathway in myelodysplastic syndromes with ineffective erythropoiesis
21. Functional expression of Fas antigen (CD95) on hematopoietic progenitor cells
22. Fas ligand is present in human erythroid colony-forming cells and interacts with Fas induced by interferon gamma to produce erythroid cell apoptosis
23. Apoptotic role of Fas/Fasligand system in the regulation of erythropoiesis
24. Sequential activation of ICE-like and CCP32-like proteases during Fas-mediated apoptosis
25. Les caspases, les protéases à cystéine de l'apoptose: un enjeu thérapeutique pour demain?
26. Negative regulation of erythropoiesis by caspase-mediated clivage of GATA-1
27. Caspase activation is required for terminal erythroid differentiation
28. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cell in 50 patients with myelodysplastic syndromes
29. Apoptosis in bone marrow of myelodysplastic syndrome patients
30. Is apoptosis a massive process in myelodysplastic syndromes?
31. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes
32. Fas ligand expression in the bons marrow in myelodysplastic syndromes correlates with FAB subtype and anemia, and predicts survival
33. The activity of the caspase-3/CPP32 enzyme is increased in "early stage" myelodysplastic syndromes with excessive apoptosis, but caspase inhibition does not enhance colony formation in vitro
34. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells
35. The role of apoptosis, proliferation and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemias secondary to MDS
36. Increased apoptosis in mononucleated cells but not in CD34+ cells in blastic forms of myelodysplastic syndromes
37. The relative extent and propensity of CD34+ vs. CD34-cells to undergo apoptosis in myelodysplastic marrows
38. Haematological response of patients with myelodysplastic syndromes to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vb profiles
39. Vascular cell adhesion molecule-1 expressed by bone marrow stromal cells mediates the binding of hematopoietic progenitor cells
40. Expression and secretion of VEGF-A by cytokine-stimulated hematopoietic progenitor cells. Possible role in the hematopoietic microenvironment
41. Neuropilin-1 is expressed on bone marrow stromal cells: A novel interaction with hematopoietic cells?
42. Functional studies of bone marrow haematopoietic and stromal cells in the myelodysplastic syndrome (MDS)
43. Blast-colony forming cell-binding capacity of bone marrow stroma from myelodysplatic patients
44. Bone marrow stroma from myelodysplastic syndromes is defective in its ability to support normal CD34+ cell proliferation and differentiation in vitro
45. Reduced expression of a5b1 integrins on CD34+ marrow progenitors of MDS patients with high levels of apoptosis
46. Reduced expression but functional integrity of α4β1 and α5β1 integrins on hematopoietic progenitors of MDS patients with high levels of intramedullary apoptosis
47. Cytokine expression in adherent layers from patients with myelodysplastic syndromes and acute myelogenous leukemias
48. A role for tumor necrosis factor-alpha, Fas and Fas-ligand in marrow failure associated with myelodysplastic syndrome
49. Is acquired idiopathic sideroblastic anemia (AISA) a disorder of mitochondrial DNA?